New mutation linked to non-Hodgkin's lymphoma

Nov 01, 2010

Some patients with non-Hodgkin lymphoma (NHL) -- a cancer of B cells -- harbor a particular mutation in the gene encoding the receptor for B cell activating factor (BAFF), according to a paper published online on November 1 in the Journal of Experimental Medicine. BAFF, a soluble protein needed for B cell survival and maturation, is elevated in the blood of some NHL patients and is associated with poor prognosis.

This BAFF-R mutation, identified by a team led by Anne Novak and Gail Bishop, generates a receptor that transmits stronger than normal signals, thus boosting function.

Although present in fewer than 10% of the tumors analyzed in the study, this mutation provides further evidence of the importance of BAFF signaling in this dangerous malignancy.

Explore further: New cancer drug target involving lipid chemical messengers

More information: Hildebrand, J.M., et al. 2010. J. Exp. Med. doi:10.1084/jem.20100857

add to favorites email to friend print save as pdf

Related Stories

Baffling the body into accepting transplants

Jan 21, 2009

An unexpected discovery made by a Sydney scientist has potential to alter the body's response to anything it perceives as not 'self', such as a tissue or organ transplant.

SHIP protein identified as a B-cell tumor suppressor

Oct 19, 2010

Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally throughout the body. Lymphomas can arise from two types of white blood cells, T cells or B cells, which divide uncontrollably ...

'Junk DNA' drives cancer growth

May 02, 2010

Researchers from the University of Leeds, UK, the Charite University Medical School and the Max Delbruck Centre for Molecular Medicine (MDC) in Berlin, Germany, have discovered a new driving force behind cancer growth.

Recommended for you

User comments : 0